Efzofitimod
Small moleculeexperimentalCOVID-19
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jan 29, 2019 (NCT03824392)
Timeline
Indications
Mechanism of action
- Neuropilin-2MODULATOR
modulator - nrp2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05892614 | Phase 2 | Oct 26, 2023 | aTyr Pharma |
| NCT05415137 | Phase 3 | Sep 15, 2022 | aTyr Pharma, Kyorin Pharma |
| NCT04412668 | Phase 2 | Jun 1, 2020 | aTyr Pharma |
| NCT03824392 | Phase 1/Phase 2 (Phase 2) | Jan 29, 2019 | aTyr Pharma, Foundation for Sarcoidosis Research |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| aTyr Pharma | For profit | 4 | 4 | 2 | 2019 |
| Foundation for Sarcoidosis Research | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Kyorin Pharma | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1